zProf. Dr. Johann Bauersachs

Director of the Department of Cardiology and Angiology

Curriculum vitae
  • 1993
    Thesis (M.D.) at the University of Freiburg, Department of Physiology
  • 1993 – 1995
    Residency and Fellowship in Internal Medicine, University Hospital Frankfurt
  • 1995 – 1996
    Postdoctoral/Research Associate, Physiology, University of Frankfurt
  • 1996 – 1999
    Residency and Fellowship in Internal Medicine, University Hospital Mannheim
  • 1999 – 2003
    Residency and Fellowship in Internal Medicine and Cardiology, Department of Medicine, University of Würzburg
  • 1999 – 2004
    Scientific Secretary DFG Special Research Program SFB 355
  • 2000
    Board Certification „Internal Medicine“
  • 2002
    Board Certification „Cardiology“
  • 2001
    Habilitation, Member of the Faculty, senior lecturer, Dept. of Medicine, Division of Cardiology, University of Würzburg
  • 2003 – 2010
    Consultant Cardiology/Intensive Care, University Hospital Würzburg
  • 2006 – 2010
    Scientific Secretary DFG Special Research Program SFB 688
  • 2008
    Board Certification „Intensive Care”
  • 2008 – 2010
    Associate Professor, Dept. of Medicine I, University Hospital Würzburg
  • 2010
    Call for W3-Professorship Cardiology/Angiology, University Hospital Giessen
  • since 2010
    Full Professor and Director, Department of Cardiology and Angiology, Hannover Medical School
  • since 2014
    DGK-Certificate „Additional qualification Interventional Cardiology
  • since 2018
    DGK-Certificate „Additional qualification Heart Failure“
Special achievements/honors
  • 2001
    Oskar-Lapp- Award, „Deutsche Gesellschaft für Kardiologie“
  • 2004
    Albert-Fraenkel-Award, „Deutsche Gesellschaft für Kardiologie“
  • 2006
    Parmley-Award, American College of Cardiology
  • 2012
    Bernard and Joan Marshall Distinguished Investigator Award, British Society for Cardiovascular Research
  • 2016
    Honorary member of "Corean Society of Cardiology"
  • 2018

    Paul Morawitz-Award, „Deutsche Gesellschaft für Kardiologie"

  • 2019
    Honorary member of the "Romanian Society of Cardiology"
  • 2021

    Silver Badge of Honour, German Cardiac Society

  • PCT/EP2007/008772: microRNA (miRNA) for the diagnosis and treatment of heart diseases
  • PCT/EP2009/051986: MicroRNA (miRNA) and downstream targets for diagnostic and therapeutic purposes
Speaker of
  • Speaker of the Clinical Research Group (KFO) 311, “(Pre-)terminal heart and lung failure – mechanical unloading and repair”(https://www.kfo311.de/), funded by the Deutsche Forschungsgemeinschaft/DFG
Member of
  • Member of the DFG Cardiovascular Review Board (Fachkollegium Medizin) 2012-2020, Chair 2016-2020
  • European Society of Cardiology (ESC), Fellow, Heart Failure Association (HFA) of the ESC, Fellow
    Chair of the HFA Study Group Peripartum Cardiomyopathy
    HFA Board member 2013-2020, Chair of the HFA Clinical Section 2018-20
    Member of the ESC Congress Programme Committee 2014-18, and 2020-2022
    Member of the ESC Communication Committee 2020-2022
    Chair of the ESC Working Group on Myocardial Function 2012-2014
    Member of the ESC Guidelines Task Forces "Management of cardiovascular diseases during pregnancy 2018", and "Management of acute coronary syndromes in patients presenting without persistent ST-Segment Elevation 2020"
  • German Cardiac Society (DGK), Board Member 2017-23

    Member of the Committee on Clinical Cardiovascular Medicine 2017-21, Chair 2019-21

    Congress President “DGK Herztage 2018”; Member of the DGK Program Committee 2014-2018

    Member of the DGK Program Committee 2014-2018
  • DIGIT-HF Study (http://digit-hf.de/): “DIGitalis to Improve ouTcomes in patients with advanced chronic Heart Failure, funded by BMBF (Bundesministerium für Bildung und Forschung), Study Chair
  • Cardior Pharmaceuticals (www.cardior.de/), Advisory Board Member 2017-21
President of

ESAC Germany (European Section of Aldosterone Council) Association; President

Editorial Board Member

Deputy Editor

European Heart Journal


Associate Editor

Cardiovascular Research, Current Heart Failure Reports


Editorial Board Mitglied

Basic Research in Cardiology, Clinical Research in Cardiology, ESC Heart Failure, Herz – Cardiovascular Diseases


Reviewer for

Deutsche Forschungsgemeinschaft, Deutsche Herzstiftung, INSERM und ANR-Frankreich, Circulation, Circulation Research, Hypertension, JACC, Cardiovascular Research, European Heart Journal, European Journal of Heart Failure, etc

Research interest | Metrics

Professor Bauersachs is an interventional cardiologist with special interests in acute coronary syndromes, left ventricular healing and remodelling, acute and chronic heart failure, as well as intensive care. He is particularly interested in the pathophysiology and treatment of peripartum cardiomyopathy, in aldosterone and mineralocorticoid receptor-mediated mechanisms, and the role of non-coding RNAs


Metrics (web of science)
Publications 878
H index 84

Important recent publications
  • The struggle towards a Universal Definition of Heart Failure-how to proceed? Cleland JGF, Pfeffer MA, Clark AL, Januzzi JL, McMurray JJV, Mueller C, Pellicori P, Richards M, Teerlink JR, Zannad F, Bauersachs J. Eur Heart J. 2021;42:2331-2343. doi: 10.1093/eurheartj/ ehab082 

  • Bauersachs J. Heart failure drug therapy – the fantastic four. Eur Heart J. 2021; 42:681-683. doi: 10.1093/eurheartj/ehaa1012.
  • Diekmann J, Koenig T, Zwadlo C, Derlin T, Neuser J, Thackeray JT, Schäfer A, Ross TL, Bauersachs J, Bengel FM. Molecular Imaging Identifies Fibroblast Activation Beyond the Infarct Region After Acute Myocardial Infarction. J Am Coll Cardiol. 2021;77:1835-1837. doi: 10.1016/j.jacc.2021.02.019.

  • Bueno H, Moura B, Lancellotti P, Bauersachs J. The year in cardiovascular medicine 2020: heart failure and cardiomyopathies. Eur Heart J. 2021 Jan 3:ehaa1061. doi: 10.1093/eurheartj/ehaa1061.

  • Sliwa K, van der Meer P, Petrie MC, …, Lyon AR, Rosano G, Seferovic PM, Bauersachs J. Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. Eur J Heart Fail. 2021;23):527-540. doi: 10.1002/ejhf.2133.
  • Täubel J, Hauke W, Rump S, Viereck J, Batkai S, Poetzsch J, Rode L, Weigt H, Genschel C, Lorch U, Theek C, Levin AA, Bauersachs J, Solomon SD, Thum T. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. Eur Heart J. 2020 Nov 11:ehaa898. doi: 10.1093/eurheartj/ehaa898.

  • Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, …., Rutten FH, Sibbing D, Siontis GCM. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.  Eur Heart J 2020; doi: 10.1093/eurheartj/ehaa575.

  • Sliwa K, Petrie MC, van der Meer P, Mebazaa A, Hilfiker-Kleiner D, Jackson AM, Maggioni AP, Laroche C, Regitz-Zagrosek V, …., Ponikowski P, Van Veldhuisen DJ, McMurray J, Bauersachs J. On behalf of the EurObservational Research Programme in conjunction with the HFA of the ESC Study Group on Peripartum Cardiomyopathy. Clinical presentation, management and 6-month outcomes in women with peripartum cardiomyopathy, an ESC EORP registry. Eur Heart J 2020, in press.

  • Rassaf T, Totzeck M, Backs J, Bokemeyer C, Hallek M, Hilfiker-Kleiner D, Hochhaus A, Lüftner D, Müller OJ, Neudorf U, Pfister R, von Haehling S, Lehmann LH, Bauersachs J. Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. Clin Res Cardiol. 2020 doi: 10.1007/s00392-020-01636-7.

  • Moulig V, Pfeffer TJ, Ricke-Hoch M, Schlothauer S, Koenig T, …., Duncker D, Veltmann C, Hilfiker-Kleiner D, Bauersachs J. Long-term follow-up in peripartum cardiomyopathy patients with contemporary treatment: low mortality, high cardiac recovery, but significant cardiovascular co-morbidities. Eur J Heart Fail. 2019; 12:1534-1542. doi: 10.1002/ejhf.1624.

  • Bauersachs J, König T, van der Meer P, Petrie MC, Hilfiker-Kleiner D, …, Anker SD, Ponikowski P, Seferovic PM, Johnson MR, Mebazaa A, Sliwa K. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the HFA of the ESC Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2019. doi: 10.1002/ejhf.1493.

  • Malek Mohammadi M, Kattih B, Grund A, Froese N, Korf-Klingebiel M, Gigina A, Schrameck U, Rudat C, Liang Q, Kispert A, Wollert KC, Bauersachs J, Heineke J. The transcription factor GATA4 promotes myocardial regeneration in neonatal mice. EMBO Mol Med. 2019; 6. pii: e10678. doi: 10.15252/  emmm.201910678.

  • Bavendiek U, Berliner D, Aguirre Dávila L, …,  v. d. Leyen H, Schröder C,  Veltmann C, Störk S, Böhm M, Koch A, Bauersachs J. Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study. Eur J Heart Fail, 2019 21(5):676-684. doi: 10.1002/ejhf.1452.

  • Riehle C, Bauersachs J. Small animal models of heart failure. Cardiovasc Res  2019;115(13):1838-1849. doi: 10.1093/cvr/cvz161.

  • Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, Iung B, ..., Swan L, Warnes CA. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018, 39: 3165-3241. doi: 10.1093/eurheartj/ehy340.

  • Koehler F, Koehler K, Deckwart O, … Schulze PC, Bauersachs J, Wellge B, Schoebel C, Tajsic M, Dreger H, Anker SD, Stangl K. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. Lancet. 2018 pii: S0140-6736(18)31880-4. doi: 10.1016/S0140-6736(18)31880-4.

  • Hilfiker-Kleiner D, Haghikia A, Berliner D, Vogel-Claussen J, Schwab J, …..,  Podewski E, Böhm M, Sliwa K, Bauersachs J (2017). Bromocriptine for the Treatment of Peripartum Cardiomyopathy: A Multicenter Randomized Study. Eur Heart J 38, 2671-2679. doi: 10.1093/eurheartj/ehx355.

  • Wollert KC, Meyer GP, Müller-Ehmsen J, Tschöpe C, ….. Dickstein K, Schultheiss HP, Ladage D, Greulich S, Bauersachs J (2017). Intracoronary autologous bone marrow cell transfer after myocardial infarction:  the BOOST-2 randomised placebo-controlled clinical trial. Eur Heart J, doi: 10.1093/eurheartj/ehx188.

  • Bavendiek U,  Aguirre Davila L, Koch A, Bauersachs J (2017). Assumption versus evidence – the case of digoxin in atrial fibrillation and heart failure. Eur Heart J, pii: ehw577. doi: 10.1093/eurheartj/ehw577.

  • Bauersachs J, Arrigo M, Denise Hilfiker-Kleiner DF, ....., Seferovic P, Tavazzi L, Ruschitzka F, Mebazaa A, Sliwa K (2016). Current management of patients with severe acute peripartum cardiomyopathy: Practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 18, 1096-105.

  • Bauersachs J, Jaisser F, Toto R Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension 2015; 65, 257-263.

  • Hilfiker-Kleiner D, Haghikia A, Nonhoff J, Bauersachs J (2015). Peripartum cardiomyopathy: current management and future perspectives. Eur Heart J, DOI: 10.1093/eurheartj/ehv009.

  • Zwadlo C, Schmidtmann E, Szaroszyk M, …, Hinz H, Schmitto JD, Widder J, Batkai S, Bähre H, Kaever V, Thum T, Bauersachs J, Heineke J (2015). Anti-androgenic therapy with finasteride attenuates cardiac hypertrophy and left ventricular dysfunction. Circulation, 131:1071-1081.

  • Fraccarollo D, Berger S, Galuppo P, Kneitz S, Hein L, Schütz G, Frantz S, Ertl G, Bauersachs J. (2011). Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 123, 400-408.

  • Bauersachs J, Thum T (2011). Biogenesis and regulation of cardiovascular microRNAs. Circ Res 109, 334-47.

  • Thum T, Schmitter K, Fleissner F, Wiebking V, Dietrich B, Widder JD, Jazbutyte V, Hahner S, Ertl G, Bauersachs J (2011). Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans. Eur Heart J 32, 1275-86.

  • Thum T, Gross C, Fischer T, Fiedler J, Just S, Rottbauer W, Bussen M, Galuppo P, Frantz S, Castoldi M, Muckenthaler M, Soutschek J, Koteliansky V, Rosenwald A, Bauersachs J*, Engelhardt S* (2008). MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456, 980-984 *joint senior authors.

  • Fraccarollo D, Widder JD, Galuppo P, Thum T, Hoffmann M, Ruetten H, Ertl G, Bauersachs J (2008). Improvement of left ventricular remodelling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation 118, 818-82.

  • Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, Doevendans PA, Mummery CL, Borlak J, Haverich A, Gross C, Engelhardt S, Ertl G, Bauersachs J (2007). MicroRNAs in the human heart: A clue to fetal gene reprogramming in heart failure. Circulation 116, 258-267.

Prof. Dr. Johann Bauersachs
Tel.: +49 511 532-3841
Fax: +49 511 532-5412

Aktuelle Informationen zum Coronavirus

Besuchsregelung: Unter folgenden Bedingungen sind Besuche von Angehörigen seit dem 28. August 2021 (gem. 3G Regelung) wieder möglich:

  • Anmeldung online vorab oder am Servicepoint am Haupteingang der MHH.
  • max. 2 Besucher pro Patient pro Tag für 1 Stunde in der Zeit von 13-19 Uhr (auch gleichzeitig).
  • Patienten dürfen ab dem ersten Tag des Aufenthalts besucht werden, auf unserer Intensivstation 24 ist Besuch nur nach vorheriger Rücksprache und Vereinbarung möglich.
  • vollständig Geimpfte Personen benötigen keinen Test, Impfausweis muss jedoch vorgelegt werden.
  • nicht vollständig Geimpfte und Genesene benötigen einen tagesaktuellen Test (offizielles Testzentrum), gilt auch für Kinder ab 7 Jahren.
  • die MHH bietet keine Testmöglichkeiten an.
  • Bei Fragen zu Terminen in einer unserer Ambulanzen oder im Herzkatheterlabor bitten wir Sie, sich direkt an den entsprechenden Bereich zu wenden.
  • Aktuelle Informationen zu Fortbildungsveranstaltungen finden Sie auf unserer Homepage Startseite (Termine/Veranstaltungen).
  • Weitere Informationen zum Coronavirus finden Sie unter Medizinische Hochschule Hannover: Neue Besuchsregelung für Angehörige (mhh.de).